Stock Evaluator: Galmed Pharmaceuticals Ltd. (GLMD)

Galmed Pharmaceuticals Ltd. GLMD

$0.52 -0.01 -1.49%
August 14, 2026 1:38:22 PM EST November 10, 2021 Volume: 43,202
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Biotechnology

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases and related indications. The company develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in a Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through the ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. Further, the company is developing MyBiotics, which is in pre-clinical trials for NASH and fibrosis. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform and Tissue Dynamics to develop a novel human chronic cardiac fibrosis model. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Ramat Gan, Israel.

Commentary & Analysis


Financial Summary

Share Statistics GLMD Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $3.5 $273.0 2%
Shares Out (Mil) 6.6 53.1 16%
Institutional Ownership 61.3% 92.4% 39%
Float (Mil) 6.4 40.1 14%
Beta 0.74 0.94 44%
Avg Daily Volume (000s) 38 496 25%
Price Change
(52-week)
(64.2%) 57.5% 10%
Growth GLMD Industry
Median
Percentile
(All Stocks)
Sales (5yr) na 13.6% na
Net Income (5yr) 18.6% (10.0%) 71%
EPS (5yr) 60.3% 16.0% 96
Dividends (5yr) na 0.0% na
Cash Flow (5yr) 71.2% (15.6%) 97%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates na na na
Current EPS na na na
Month Ago EPS na na na
# Rev Up na na na
# Rev Down na na na
Three Months Ago EPS na na na
Year/Year Chg na na na
Financials GLMD Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) na $37 na
Net Income (TTM) (Mil) ($11) ($43) 28%
EPS (TTM) ($2.016) ($1.500) 14%
Operating Cash Flow (TTM) (Mil) ($8) ($31) 22%
Net Cash Flow (TTM) (Mil) na $2 na
Long-Term Debt (Q1) (Mil) $0 $4 0%
Enterprise Value (Q1) (Mil) ($12) $166 2%
Valuation GLMD Industry
Median
Percentile
(All Stocks)
P/B 0.25 2.71 4%
P/E na 18.9 na
Dividend Yield na 0.0% na
PEG (5yr hist) na 0.9 na
Ratios GLMD Industry
Median
Percentile
(All Stocks)
Gross Margin na 64.2% na
Net Margin na (73.0%) na
ROA (64.0%) (47.7%) 9%
ROE (72.1%) (55.1%) 12%
Liabilities to Assets 13.0% 29.8% 8%
F-Score 1 3 1%

Galmed Pharmaceuticals Ltd. did not pass any screens on 8/14/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors